



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 12:01  
**Last Report Issued** 03/13/2013 06:32

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 1515B  
**Patient ID** 1515B  
**Chain** 13001133  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 13001133  
**Received** 03/13/2013 06:28

**Sample ID** 13001133-001  
**Matrix** Blood  
**Patient Name** 1515B  
**Patient ID** 1515B  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**1515B Diazoxide, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Diazoxide	None Detected	ng/mL	1000	
Synonym(s): Proglycem®; Hyperstat®				
Plateau plasma concentrations following 300 mg intravenous injection of diazoxide ranged from 15000 to 25000 ng/mL.				
The blood to plasma ratio of diazoxide is not known.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.